[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608715":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":34,"responsibleParty":94,"collaborators":25,"id":96,"slug":25,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":25,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":25,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":25,"overallStatus":50,"whyStopped":25,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Forte Biosciences, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"FB102","ACTIVE_COMPARATOR","Participants will receive FB102.",[13],"Drug: FB102",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matching placebo",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Route of administration- Intravenous (IV)",[9],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Support Officer","CONTACT","+61 3 7050 1941","recruitment@clinibase.com",[35,48,58,67,76,85],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":25},"St Leonards","NOT_YET_RECRUITING","Saint Leonards","New South Wales (nsw)","2065","Australia",{"type":43,"coordinates":44},"Point",[45,46],144.71803,-38.17051,{"lat":46,"lon":45},{"facility":49,"status":50,"city":49,"state":51,"zip":52,"country":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":25},"Coorparoo","RECRUITING","Queensland","4151",{"type":43,"coordinates":54},[55,56],153.05826,-27.49325,{"lat":56,"lon":55},{"facility":59,"status":37,"city":59,"state":60,"zip":61,"country":41,"cosmosGeoPoint":62,"geoPoint":66,"contacts":25},"South Yarra","Victoria","3141",{"type":43,"coordinates":63},[64,65],144.99149,-37.83834,{"lat":65,"lon":64},{"facility":68,"status":37,"city":68,"state":68,"zip":69,"country":70,"cosmosGeoPoint":71,"geoPoint":75,"contacts":25},"Auckland","0632","New Zealand",{"type":43,"coordinates":72},[73,74],174.76349,-36.84853,{"lat":74,"lon":73},{"facility":77,"status":37,"city":77,"state":78,"zip":79,"country":70,"cosmosGeoPoint":80,"geoPoint":84,"contacts":25},"Christchurch","Canterbury","8013",{"type":43,"coordinates":81},[82,83],172.63333,-43.53333,{"lat":83,"lon":82},{"facility":86,"status":37,"city":86,"state":87,"zip":88,"country":70,"cosmosGeoPoint":89,"geoPoint":93,"contacts":25},"Palmerston North","Palmerston North Central","4414",{"type":43,"coordinates":90},[91,92],175.61113,-40.35636,{"lat":92,"lon":91},{"type":95,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100608715",false,"NCT07205159","A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.","A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.","Inclusion Criteria:\n\n* Males aged 18-60 years and females aged 18-75 years at Screening.\n* Clinical diagnosis of severe to very severe AA with ≥50% scalp hair loss (including AT or AU) confirmed by SALT score and central photo review; no other cause of hair loss.\n\n  * AT = complete scalp hair loss; AU = complete scalp, facial, and body hair loss. Note: There are additional inclusion criteria. The study center will determine if participant meets all of the criteria\n\nExclusion Criteria:\n\n* Other types of alopecia (e.g., diffuse AA, traction, scarring alopecia, telogen effluvium, trichotillomania, chemotherapy-induced hair loss, androgenetic alopecia).\n* Other scalp diseases impacting AA assessment (e.g., psoriasis, dermatitis, tinea capitis).\n* Active systemic diseases causing hair loss (e.g., lupus, thyroiditis, systemic sclerosis, lichen planus, syphilis).\n\nNote: There are additional exclusion criteria. The study center will determine if participant meets all of the criteria","ALL","18 Years","75 Years",{"count":106,"type":107},32,"ESTIMATED","INTERVENTIONAL",[110],"PHASE1","This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).",[113],"Alopecia Areata","2025-11-17",{"date":116,"type":117},"2025-11-20","ACTUAL",{"date":119,"type":117},"2025-10-23",{"date":121,"type":107},"2027-03-10",{"name":5,"class":6},6]